Evidence map›Paper›PMID 33758895›Full record

ArticlemedRxiv : the preprint server for health sciences2021

Rapid implementation of a cohort for the study of post-acute sequelae of SARS-CoV-2 infection/COVID-19.

Michael J Peluso, J Daniel Kelly, Scott Lu, Sarah A Goldberg, Michelle C Davidson, Sujata Mathur, Matthew S Durstenfeld, Matthew A Spinelli, Rebecca Hoh, Viva Tai and 37 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

47 authors.

Michael J PelusoDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, USA.
J Daniel KellyDepartment of Epidemiology and Biostatistics, University of California, San Francisco, USA.
Scott LuDepartment of Epidemiology and Biostatistics, University of California, San Francisco, USA.
Sarah A GoldbergDepartment of Epidemiology and Biostatistics, University of California, San Francisco, USA.
Michelle C DavidsonDepartment of Epidemiology and Biostatistics, University of California, San Francisco, USA.
Sujata MathurDepartment of Epidemiology and Biostatistics, University of California, San Francisco, USA.
Matthew S DurstenfeldDivision of Cardiology, Zuckerberg San Francisco General Hospital, University of California, San Francisco, USA.
Matthew A SpinelliDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, USA.
Rebecca HohDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, USA.
Viva TaiDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, USA.
Emily A FehrmanDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, USA.
Leonel TorresDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, USA.
Yanel HernandezDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, USA.
Meghann C WilliamsDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, USA.
Mireya I ArreguinDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, USA.
Jennifer A BautistaDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, USA.
Lynn H NgoDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, USA.
Monika DeswalDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, USA.
Sadie E MunterDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, USA.
Enrique O MartinezDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, USA.
Khamal A AnglinDepartment of Epidemiology and Biostatistics, University of California, San Francisco, USA.
Mariela D RomeroDepartment of Epidemiology and Biostatistics, University of California, San Francisco, USA.
Jacqueline TavsDepartment of Epidemiology and Biostatistics, University of California, San Francisco, USA.
Paulina R RugartDepartment of Epidemiology and Biostatistics, University of California, San Francisco, USA.
Jessica Y ChenDepartment of Epidemiology and Biostatistics, University of California, San Francisco, USA.
Hannah M SansDepartment of Epidemiology and Biostatistics, University of California, San Francisco, USA.
Victoria W MurrayDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, USA.
Payton K EllisDepartment of Epidemiology and Biostatistics, University of California, San Francisco, USA.
Kevin C DonohueDepartment of Epidemiology and Biostatistics, University of California, San Francisco, USA.
Jonathan A MassachiDepartment of Epidemiology and Biostatistics, University of California, San Francisco, USA.
Jacob O WeissDepartment of Epidemiology and Biostatistics, University of California, San Francisco, USA.
Irum MehdiDepartment of Epidemiology and Biostatistics, University of California, San Francisco, USA.
Jesus Pineda-RamirezDepartment of Epidemiology and Biostatistics, University of California, San Francisco, USA.
Alex F TangDepartment of Epidemiology and Biostatistics, University of California, San Francisco, USA.
Megan WengerDepartment of Epidemiology and Biostatistics, University of California, San Francisco, USA.
Melissa AssenzioDepartment of Epidemiology and Biostatistics, University of California, San Francisco, USA.
Yan YuanDepartment of Epidemiology and Biostatistics, University of California, San Francisco, USA.
Melissa KroneDepartment of Epidemiology and Biostatistics, University of California, San Francisco, USA.
Rachel L RutishauserDivision of Experimental Medicine, University of California, San Francisco, USA.
Isabel Rodriguez-BarraquerDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, USA.
Bryan GreenhouseDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, USA.
John A SaucedaCenter for AIDS Prevention Studies, University of California, San Francisco, USA.
Monica GandhiDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, USA.
Priscilla Y HsueDivision of Cardiology, Zuckerberg San Francisco General Hospital, University of California, San Francisco, USA.
Timothy J HenrichDivision of Experimental Medicine, University of California, San Francisco, USA.
Steven G DeeksDivision of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, USA.
Jeffrey N MartinDepartment of Epidemiology and Biostatistics, University of California, San Francisco, USA.

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jae M. Sevelius · 1988 to 2026
$93.6M
MOLECULAR AND CELLULAR BASIS OF CARDIOVASCULAR DISEASET32HL007731 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Brian L Black · 1992 to 2026
$12.4M
Training in HIV Translational ResearchT32AI060530 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Diane V Havlir · 2005 to 2026
$6.4M
Targeting Non Viral Markers of HIV PersistenceR01AI141003 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HENRICH, TIMOTHY JENSEN · 2018 to 2022
$4.9M
Evaluation of the Interplay between HIV and COVID-19 in a large urban safety-net HIV clinicR01AI158013 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GANDHI, MONICA, SPINELLI, MATTHEW A. · 2020 to 2023
$3.1M
Role of Hematopoietic System and Proteomics in HIV-Associated CardiovascularDiseaseK24AI112393 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HSUE, PRISCILLA Y. · 2014 to 2024
$1.9M
Understanding the epidemiology and natural history of unrecognized Ebola virus infectionK23AI146268 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KELLY, JOHN DANIEL · 2019 to 2022
$748k
NHLBI NIH HHS T32 HL007731NIAID NIH HHS K23 AI146268NIAID NIH HHS K24 AI112393NIAID NIH HHS P30 AI027763NIAID NIH HHS R01 AI141003NIAID NIH HHS R01 AI158013NIAID NIH HHS T32 AI060530
6 · The paper itself

Abstract

backgroundAs the coronavirus disease 2019 (COVID-19) pandemic continues and millions remain vulnerable to infection with severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), attention has turned to characterizing post-acute sequelae of SARS-CoV-2 infection (PASC).

methodsFrom April 21 to December 31, 2020, we assembled a cohort of consecutive volunteers who a) had documented history of SARS-CoV-2 RNA-positivity; b) were ≥ 2 weeks past onset of COVID-19 symptoms or, if asymptomatic, first test for SARS-CoV-2; and c) were able to travel to our site in San Francisco. Participants learned about the study by being identified on medical center-based registries and being notified or by responding to advertisements. At 4-month intervals, we asked participants about physical symptoms that were new or worse compared to the period prior to COVID-19, mental health symptoms and quality of life. We described 4 time periods: 1) acute illness (0-3 weeks), 2) early recovery (3-10 weeks), 3) late recovery 1 (12-20 weeks), and 4) late recovery 2 (28-36 weeks). Blood and oral specimens were collected at each visit.

resultsWe have, to date, enrolled 179 adults. During acute SARS-CoV-2 infection, 10 had been asymptomatic, 125 symptomatic but not hospitalized, and 44 symptomatic and hospitalized. In the acute phase, the most common symptoms were fatigue, fever, myalgia, cough and anosmia/dysgeusia. During the post-acute phase, fatigue, shortness of breath, concentration problems, headaches, trouble sleeping and anosmia/dysgeusia were the most commonly reported symptoms, but a variety of others were endorsed by at least some participants. Some experienced symptoms of depression, anxiety, and post-traumatic stress, as well as difficulties with ambulation and performance of usual activities. The median visual analogue scale value rating of general health was lower at 4 and 8 months (80, interquartile range [IQR]: 70-90; and 80, IQR 75-90) compared to prior to COVID-19 (85; IQR 75-90). Biospecimens were collected at nearly 600 participant-visits.

conclusionAmong a cohort of participants enrolled in the post-acute phase of SARS-CoV-2 infection, we found many with persistent physical symptoms through 8 months following onset of COVID-19 with an impact on self-rated overall health. The presence of participants with and without symptoms and ample biological specimens will facilitate study of PASC pathogenesis. Similar evaluations in a population-representative sample will be needed to estimate the population-level prevalence of PASC.

Identifiers

PMID33758895
PMCPMC7987054

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.